ArticleJournal of molecular medicine (Berlin, Germany)2009
Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.
Article in Journal of molecular medicine (Berlin, Germany), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 3 syntheses or guidelines pooled it, 186 citations in OpenAlex.
- The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review ofCannabis and cannabinoid research · 2021Pooled it
- Cannabis for the treatment of ulcerative colitis.The Cochrane database of systematic reviews · 2018Pooled it
- Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?Redox biology · 2015Pooled it
- Effects of Cannabidiol Supplementation on Skeletal Muscle Regeneration after Intensive Resistance Training.Nutrients · 2021Trial
- Cannabidiol for Mucosal Diseases: Therapeutic Potential and Advanced Delivery Strategies.Pharmaceutics · 2026Review
- Cannabidiol Use in Inflammatory Bowel Disease: Insights From a Gastroenterology Outpatient Population.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- A novel enema formulation containing cannabidiol and sodium propionate for ulcerative colitis: preclinical assessment in a murine model.Journal of cannabis research · 2026Article
- Cannabidiol mitigates high-fat-diet-induced early-stage inflammation in two adipose tissue fat depots of Wistar rats.Scientific reports · 2026Article
- Barrier-Strengthening Effects of Cannabidiol on Porcine Peyer's Patches.International journal of molecular sciences · 2025Article
- Emerging Natural Therapies for the Treatment of Inflammatory Bowel Disease.Current pharmaceutical biotechnology · 2025Review
- Influence of short-term chronic oral cannabidiol application on muscle recovery and performance after an intensive training protocol - a randomized double-blind crossover study.Journal of the International Society of Sports Nutrition · 2024Article
- Cannabidiol Enhances Mitochondrial Metabolism and Antioxidant Defenses in Human Intestinal Epithelial Caco-2 Cells.Nutrients · 2024Article
- The Potential of Cannabis in Managing Inflammatory Bowel Disease and Its Future Perspective.Cureus · 2024Review
- Article
- Review
- Polycaprolactone microparticles for the subcutaneous administration of cannabidiol: in vitro and in vivo release.Drug delivery and translational research · 2024Article
- Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition.International journal of molecular sciences · 2024Review
- The NLRP3 inflammasome: a vital player in inflammation and mediating the anti-inflammatory effect of CBD.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects.Molecules (Basel, Switzerland) · 2024Review
- The effect of cannabis-derived terpenes on alveolar macrophage function.Frontiers in toxicology · 2024Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease affects millions of individuals; nevertheless, pharmacological treatment is disappointingly unsatisfactory. Cannabidiol, a safe and non-psychotropic ingredient of marijuana, exerts pharmacological effects (e.g., antioxidant) and mechanisms (e.g., inhibition of endocannabinoids enzymatic degradation) potentially beneficial for the inflamed gut. Thus, we investigated the effect of cannabidiol in a murine model of colitis. Colitis was induced in mice by intracolonic administration of dinitrobenzene sulfonic acid. Inflammation was assessed both macroscopically and histologically. In the inflamed colon, cyclooxygenase-2 and inducible nitric oxide synthase (iNOS) were evaluated by Western blot, interleukin-1beta and interleukin-10 by ELISA, and endocannabinoids by isotope dilution liquid chromatography-mass spectrometry. Human colon adenocarcinoma (Caco-2) cells were used to evaluate the effect of cannabidiol on oxidative stress. Cannabidiol reduced colon injury, inducible iNOS (but not cyclooxygenase-2) expression, and interleukin-1beta, interleukin-10, and endocannabinoid changes associated with 2,4,6-dinitrobenzene sulfonic acid administration. In Caco-2 cells, cannabidiol reduced reactive oxygen species production and lipid peroxidation. In conclusion, cannabidiol, a likely safe compound, prevents experimental colitis in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.